Latest News

Management of prostate cancer after surgery is controversial. Past studies on adjuvant radiotherapy (aRT) for higher-risk features have had conflicting results. Through the collaborative conversations of the global radiation oncology Twitter-based journal club (#RadOnc #JC), we explored this complex topic to share recent advances, better understand what the global radiation oncology community felt was important […]

Fibroblast activation protein-α (FAP) is a transmembrane peptidase and a surrogate marker for cancer-associated fibroblasts (CAFs). FAP has been linked to worse prognosis and therapy resistance in several cancers.

To investigate the role of clinical parameters and immunohistochemical (IHC) biomarkers in their feasibility to predict the effect of neo-adjuvant chemotherapy (NAC) in patients with muscle-invasive urothelial bladder cancer (MIBC).

(UroToday.com) In the on-demand poster session of the European Society for Medical Oncology (ESMO) Annual Congress, Dr. Rosenberg reported long-term follow-up of the IMvigor210 Cohort 1. While cisplatin-based chemotherapy is the standard of care for first-line (1L) metastatic urothelial carcinoma (mUC), many patients are ineligible for treatment with cisplatin. Thus, Cohort 1 of the single-arm […]

Diane Newman: Welcome everyone. I’m Diane Newman, a nurse practitioner specialist at the University of Pennsylvania in Philadelphia. My practice is in urology. And I’m here today for UroToday, to introduce a speaker that I heard at the American Urologic Association, Dr. Curtis Nickel.  I’ve known him for many years, way back he and I […]

(UroToday.com) In the on-demand poster session of the European Society for Medical Oncology (ESMO) Annual Congress, Dr. Jonathan Rosenberg presented a subgroup analysis of the EV-301 trial. This phase III trial (NCT03474107) demonstrated that treatment with enfortumab vedotin (EV) showed superior overall survival (OS) compared with standard chemotherapy (SC) in patients with previously treated locally advanced […]

(UroToday.com) In the on-demand poster session of the European Society for Medical Oncology (ESMO) Annual Congress, Dr. Eugene Shenderov presented results of a phase 2 trial of the anti–B7-H3 antibody, enoblituzumab, in men with localized prostate cancer. B7-H3, a member of the B7 superfamily, is highly expressed (relative to PD-L1 and PD-L2) in prostate cancer. Further, […]

(UroToday.com) In the on-demand poster session of the European Society for Medical Oncology (ESMO) Annual Congress, Dr. Eugene Shenderov presented preliminary results of a phase I cohort expansion testing MGC018, an investigational ADC with a duocarmycin payload linked to an anti-B7-H3 monoclonal antibody, in patients with metastatic castration resistant prostate cancer (mCRPC).

(UroToday.com) As a portion of the European Society for Medical Oncology (ESMO) Annual Congress, an Educational Session focused on precision management of patients with prostate cancer was held. In this context, Dr. Cora Sternberg presented clinical perspectives for both individual patients and for the community. She began by highlighting that personalized cancer medicine has been popularized […]

(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 annual meeting’s prostate cancer session included a presentation by Dr. Bertrand Tombal discussing a subgroup analysis of the phase 3 HERO study assessing the efficacy and safety of relugolix versus leuprolide among men with advanced prostate cancer. Androgen deprivation therapy is a cornerstone of prostate cancer […]